Developing a QSAR model for hepatotoxicity screening of the active compounds in traditional Chinese medicines

Food and Chemical Toxicology

Volumn 78, Issue , 2015, Pages 71-77

  Huang, Shan Han ^a   Tung, Chun Wei ^a,b   Fülöp, Ferenc ^c   Li, Jih Heng ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Drug induced liver injury (DILI); Hepatotoxicity; QSAR; Traditional Chinese medicine

Indexed keywords

DIHYDROKAWAIN; EPHEDRINE; EPIGALLOCATECHIN GALLATE; GINSENOSIDE RB 1; GINSENOSIDE RG 1; GUMMIFERIN; HERBACEOUS AGENT; ISOSILYBIN; KAWAIN; NORDIHYDROGUAIARETIC ACID; PLANT MEDICINAL PRODUCT; PYRROLIZIDINE ALKALOID; SAIKOSAPONIN B1; SAIKOSAPONIN B2; SAPONIN DERIVATIVE; SILIBININ; SILICRISTIN; SILIDIANIN; TETRAHYDROPALMATINE; UNCLASSIFIED DRUG; USNIC ACID;

ARTICLE; CHINESE MEDICINE; COMPUTER MODEL; DRUG SAFETY; DRUG SCREENING; HERBAL MEDICINE; KNOWLEDGE BASE; LIVER TOXICITY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; TAIWAN; TOXIC HEPATITIS; VALIDATION PROCESS; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; FACTUAL DATABASE; HUMAN; LIVER; PATHOLOGY; REPRODUCIBILITY; THEORETICAL MODEL;

ANIMALS; DATABASES, FACTUAL; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; MEDICINE, CHINESE TRADITIONAL; MODELS, THEORETICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAIWAN;

EID: 84922982457     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2015.01.020     Document Type: Article

References (67)

1. Allen J.R., Hsu I.C., Carstens L.A. Dehydroretronecine-induced rhabdomyosarcomas in rats. Cancer Res 1975, 35:997-1002.
2. Amaratunga D., Cabrera J., Lee Y.S. Enriched random forests. Bioinformatics 2008, 24:2010-2014.
3. Aptula A.O., Patlewicz G., Roberts D.W. Skin sensitization: reaction mechanistic applicability domains for structure-activity relationships. Chem. Res. Toxicol 2005, 18:1420-1426.
4. Bolton E.E., Wang Y., Thiessen P.A., Bryant S.H. PubChem: integrated platform of small molecules and biological activities. Annual Reports in Computational Chemistry 2008, 217-241. Elsevier, Washington DC, USA, Chapter 12. A.W. Ralph, C.S. David (Eds.).
5. Borum M.L. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am. J. Gastroenterol 2001, 96:1654-1655.
6. Breiman L. Random forests. Mach. Learn 2001, 45:5-32.
7. Breiman L., Friedman J., Stone C.J., Olshen R.A. Classification and Regression Trees 1984, CRC Press, New York, USA.
8. Chang L.C., Huang N., Chou Y.J., Lee C.H., Kao F.Y., Huang Y.T. Utilization patterns of Chinese medicine and Western medicine under the National Health Insurance Program in Taiwan, a population-based study from 1997 to 2003. BMC Health Serv. Res 2008, 8:170.
9. Chen C.Y. TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PLoS ONE 2011, 6:e15939.
10. Chen F.P., Chen T.J., Kung Y.Y., Chen Y.C., Chou L.F., Chen F.J., et al. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv. Res 2007, 7:26.
11. Chen M., Vijay V., Shi Q., Liu Z., Fang H., Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 2011, 16:697-703.
12. Chen M., Borlak J., Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013, 58:388-396.
13. Chen M., Hong H., Fang H., Kelly R., Zhou G., Borlak J., et al. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. Toxicol. Sci 2013, 136:242-249.
14. Chen X.W., Serag E.S., Sneed K.B., Zhou S.F. Herbal bioactivation, molecular targets and the toxicity relevance. Chem. Biol. Interact 2011, 192:161-176.
15. Cheng A. In silico prediction of hepatotoxicity. Curr. Comput. Aided Drug Des 2009, 5:122-127.
16. Cheung W.I., Tse M.L., Ngan T., Lin J., Lee W.K., Poon W.T., et al. Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine. Clin. Toxicol. (Phila.) 2009, 47:683-685.
17. Chitturi S., Farrell G.C. Herbal hepatotoxicity: an expanding but poorly defined problem. J. Gastroenterol. Hepatol 2000, 15:1093-1099.
18. Chitturi S., Farrell G.C. Hepatotoxic slimming aids and other herbal hepatotoxins. J. Gastroenterol. Hepatol 2008, 23:366-373.
19. Custer L.L., Sweder K.S. The role of genetic toxicology in drug discovery and optimization. Curr. Drug Metab 2008, 9:978-985.
20. Dimitrov S.D., Low L.K., Patlewicz G.Y., Kern P.S., Dimitrova G.D., Comber M.H., et al. Skin sensitization: modeling based on skin metabolism simulation and formation of protein conjugates. Int. J. Toxicol 2005, 24:189-204.
21. Fu P.P., Xia Q., Lin G., Chou M.W. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab. Rev 2004, 36:1-55.
22. Gibb S. Toxicity testing in the 21st century: a vision and a strategy. Reprod. Toxicol 2008, 25:136-138.
23. Greene N., Fisk L., Naven R.T., Note R.R., Patel M.L., Pelletier D.J. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem. Res. Toxicol 2010, 23:1215-1222.
24. Hall M., Frank E., Holmes G., Pfahringer B., Reutemann P., Witten I.H. The WEKA data mining software: an update. SIGKDD Explor. Newsl 2009, 11:10-18.
25. Jacobs B.P., Dennehy C., Ramirez G., Sapp J., Lawrence V.A. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am. J. Med 2002, 113:506-515.
26. Jordan S.A., Cunningham D.G., Marles R.J. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol. Appl. Pharmacol 2010, 243:198-216.
27. Kane J.A., Kane S.P., Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 1995, 36:146-147.
28. Ko R.J. A U.S. perspective on the adverse reactions from traditional Chinese medicines. J. Chin. Med. Assoc 2004, 67:109-116.
29. Krewski D., Andersen M.E., Mantus E., Zeise L. Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal 2009, 29:474-479.
30. Kruger C.L., Mann S.W. Safety evaluation of functional ingredients. Food Chem. Toxicol 2003, 41:793-805.
31. Lee W.M. Drug-induced hepatotoxicity. NEJM 2003, 349:474-485.
32. Liaw C., Tung C.W., Ho S.Y. Prediction and analysis of antibody amyloidogenesis from sequences. PLoS ONE 2013, 8:e53235.
33. Licata A., Macaluso F.S., Craxi A. Herbal hepatotoxicity: a hidden epidemic. Intern. Emerg. Med 2013, 8:13-22.
34. Lin N., Wu B., Jansen R., Gerstein M., Zhao H. Information assessment on predicting protein-protein interactions. BMC Bioinformatics 2004, 5:154.
35. Mei N., Arlt V.M., Phillips D.H., Heflich R.H., Chen T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res 2006, 602:83-91.
36. Murray K.F., Hadzic N., Wirth S., Bassett M., Kelly D. Drug-related hepatotoxicity and acute liver failure. J. Pediatr. Gastroenterol. Nutr 2008, 47:395-405.
37. Nadir A., Agrawal S., King P.D., Marshall J.B. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am. J. Gastroenterol 1996, 91:1436-1438.
38. Nandy A., Kar S., Roy K. Development and validation of regression-based QSAR models for quantification of contributions of molecular fragments to skin sensitization potency of diverse organic chemicals. SAR QSAR Environ. Res 2013, 24:1009-1023.
39. Neff G.W., Reddy K.R., Durazo F.A., Meyer D., Marrero R., Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J. Hepatol 2004, 41:1062-1064.
40. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol 2006, 80:580-604.
41. Ohtake N., Nakai Y., Yamamoto M., Sakakibara I., Takeda S., Amagaya S., et al. Separation and isolation methods for analysis of the active principles of Sho-saiko-to (SST) oriental medicine. J. Chromatogr. B. Analyt Technol Biomed Life Sci 2004, 812:135-148.
42. Perkins R., Fang H., Tong W., Welsh W.J. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ. Toxicol. Chem 2003, 22:1666-1679.
43. Persson M., Loye A.F., Mow T., Hornberg J.J. A high content screening assay to predict human drug-induced liver injury during drug discovery. J. Pharmacol. Toxicol. Methods 2013, 68:302-313.
44. Petzinger E. [Pyrrolizidine alkaloids and seneciosis in farm animals. Part 1: occurrence, chemistry and toxicology]. Tierarztl. Prax. Ausg. G. Grosstiere Nutztiere 2011, 39:221-230.
45. Pittler M.H., Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment. Pharmacol. Ther 2003, 18:451-471.
46. Polishchuk P.G., Muratov E.N., Artemenko A.G., Kolumbin O.G., Muratov N.N., Kuz'min V.E. Application of random forest approach to QSAR prediction of aquatic toxicity. J. Chem. Inf. Model 2009, 49:2481-2488.
47. Roberts D.W., Aptula A.O., Patlewicz G. Mechanistic applicability domains for non-animal based prediction of toxicological endpoints. QSAR analysis of the schiff base applicability domain for skin sensitization. Chem. Res. Toxicol 2006, 19:1228-1233.
48. Rodgers A.D., Zhu H., Fourches D., Rusyn I., Tropsha A. Modeling liver-related adverse effects of drugs using κ-nearest neighbor quantitative structure-activity relationship method. Chem. Res. Toxicol 2010, 23:724-732.
49. Schoental R. Toxicology and carcinogenic action of pyrrolizidine alkaloids. Cancer Res 1968, 28:2237-2246.
50. Simmons J.E. Chemical mixtures: challenge for toxicology and risk assessment. Toxicology 1995, 105:111-119.
51. Singh P., Mishra S.K., Noel S., Sharma S., Rath S.K. Acute exposure of apigenin induces hepatotoxicity in Swiss mice. PLoS ONE 2012, 7:e31964.
52. Smith L.W., Culvenor C.C. Plant sources of hepatotoxic pyrrolizidine alkaloids. J. Nat. Prod 1981, 44:129-152.
53. Steinbeck C., Hoppe C., Kuhn S., Floris M., Guha R., Willighagen E.L. Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. Curr. Pharm. Des 2006, 12:2111-2120.
54. Stickel F., Patsenker E., Schuppan D. Herbal hepatotoxicity. J. Hepatol 2005, 43:901-910.
55. Svetnik V., Liaw A., Tong C., Culberson J.C., Sheridan R.P., Feuston B.P. Random forest: a classification and regression tool for compound classification and QSAR modeling. J. Chem. Inf. Comput. Sci 2003, 43:1947-1958.
56. Teschke R. Traditional Chinese medicine induced liver injury. J. Clin. Transl. Hepatol 2014, 2:80-94.
57. Tolosa L., Pinto S., Donato M.T., Lahoz A., Castell J.V., O'Connor J.E., et al. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol. Sci 2012, 127:187-198.
58. Tung C.-W., Liaw C., Ho S.-J., Ho S.-Y. Prediction of protein subchloroplast locations using Random Forests 2010, 26-28. Proceeding of World Academy of Science, Engineering and Technology.
59. Valencia A., Prous J., Mora O., Sadrieh N., Valerio L.G. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities. Toxicol. Appl. Pharmacol 2013, 273:427-434.
60. Valerio L.G., Cross K.P. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities. Toxicol. Appl. Pharmacol 2012, 260:209-221.
61. Vanderperren B., Rizzo M., Angenot L., Haufroid V., Jadoul M., Hantson P. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann. Pharmacother 2005, 39:1353-1357.
62. Varma S., Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 2006, 7:91.
63. Wang F., Liu D., Wang H., Luo C., Zheng M., Liu H., et al. Computational screening for active compounds targeting protein sequences: methodology and experimental validation. J. Chem. Inf. Model 2011, 51:2821-2828.
64. Wang J.B., Xiao X.H., Du X.X., Zou Z.S., Song H.B., Guo X.X. [Identification and early diagnosis for traditional Chinese medicine-induced liver injury based on translational toxicology]. Zhongguo Zhong Yao Za Zhi 2014, 39:5-9.
65. Wang L., Huang C., Yang J.Y. Predicting siRNA potency with random forests and support vector machines. BMC Genomics 2010, 11(Suppl. 3):S2.
66. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci 2008, 105:97-105.
67. Yu K., Geng X., Chen M., Zhang J., Wang B., Ilic K., et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab. Dispos 2014, 42:744-750.